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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most 
common amongst non-Hodgkin lymphomas, accounting 
for approximately 30% of all cases. Most of the times, 
disease primarily occurs in the lymph nodes, but extranodal 
involvement is not uncommon. About 30% of DLBCL cases 
present with disease outside the lymph nodes, which may 
incur different clinicopathologic features and prognosis for 
these patients (1-3). Cases involving soft tissues often mimic 
other entities like sarcoma. Treatment options remain the 
same for both nodal and extranodal DLBCL, with the first 
choice being chemoimmunotherapy including anthracyclines 
(4-10). Age and preexisting medical conditions are the 
main limiting factors in planning the treatment. Regimens 
including alternatives to the cardiotoxic therapies have 
been investigated. Phases I and II studies incorporating the 
liposomal form of doxorubicin showed promising results for 
the patients who would otherwise be deprived of the most 
effective therapies (11-13). We present a case of an elderly 
patient with right upper extremity (RUE) mass which was 
proven to be DLBCL instead of sarcoma. We emphasize the 
increasing need for investigating new therapeutic options for 
patients of extreme age and/or with underlying heart disease.
Case presentation
The patient was a 90-year-old male who was referred for 
evaluation of a RUE mass. The patient and family reported 
decreased appetite and fatigue, as well as weight loss of 
about 20 pounds in the preceding 6 months. Patient’s 
past medical history was significant for hypertension, 
cerebrovascular accident with residual expressive aphasia 
and benign prostate hyperplasia. Located in the anterior 
aspect of the right upper arm, just above the antecubital 
fossa, the mass was described as a large violaceous fleshy 
tumor of approximately 10 cm × 7 cm in size. Not tender, 
with intact skin, the lesion was associated with mild 
RUE edema. Three months earlier patient was evaluated 
by surgery for the same lesion. The ultrasound study 
of the lesion showed heterogeneous mass or collection 
of about 7.8 cm × 4.6 cm × 5.2 cm in size, MRI study 
showed a mass of 10.1 cm × 5.3 cm × 6.8 cm within the 
musculature of the right arm, as well as additional 1.4 cm 
× 1.9 cm × 2.5 cm focus surrounding the brachioradialis 
neurovascular bundle, which was in contiguity with the 
larger mass. The radiological picture was highly suggestive 
of soft tissue sarcoma or other malignant neoplasm. At 
this time, patient was reluctant to pursue further work up 
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and was noncompliant with follow up. After presenting to 
oncology the patient was referred for biopsy of the mass, 
which again he did not pursue. Two months later the 
patient was admitted to the hospital; the mass was then 
fungating and ulcerated, with purulent discharge. Patient 
was managed for wound infection. MRI of the RUE showed 
interval growth and ulceration of the mass lesion measuring 
15.4 cm × 4.9 cm × 7.7 cm, encasing the brachial vessels, as 
well as possible extension into the axilla with involvement 
of the brachial plexus. Biopsy was performed during the 
hospital stay and the H&E sections revealed multiple cores 
with diffuse proliferation of atypical lymphocytes with focal 
crush/degeneration artifacts and areas of tumor necrosis. 
Scattered entrapped skeletal muscle fibers were seen in focal 
areas. The atypical lymphocytes were large in size and had 
moderate cytoplasm, round to irregular nuclear contour, 
some indented, clumped to fine vesicular chromatin and 
some with one to multiple nucleoli. Mitosis/apoptosis were 
easily seen. Scattered small reactive lymphocytes were 
seen in the background. The atypical lymphocytes were 
diffusely positive for CD20, Pax5 and BCL2 (Figure 1), 
while they were negative for CD3, CD5, CD10, BCL6, 
BCL1, MUM-1, CD30, CD56, CD34, pancytokeratin 
(AE1/AE3), MyoD1, and HMB-45. CD3 and CD5 
highlighted background reactive small T-cells. Ki-67 
stain showed high nuclear proliferation index (85–90% of 
neoplastic cells were positive). The findings were consistent 
with DLBCL, activated B-cell like (ABC). Staging work 
up was performed. CT of the chest, abdomen and pelvis 
did not reveal any changes suspicious for disease spread, 
however bone marrow biopsy showed minimal involvement 
with B-cell lymphoma. Upon presentation patient had 
hemoglobin level 12.6 g/dL, white blood cell count 
(WBC) of 6,800/mm3 with predominance of neutrophils 
(88%) and a normal platelet  count (207 K/mm3). 
LDH was 337 U/L. Echocardiography revealed left 
ventricular ejection fraction (LVEF) of 45%. His Eastern 
Cooperative Oncology Group (ECOG) performance status 
was 2. After extensive discussion with the patient and the 
family, chemotherapy with R-CHOP regimen (rituximab, 
cyclophosphamide, doxorubicin, vincristine and prednisone) 
was advised with modifications. Due to decreased LVEF 
and advanced age the regimen included the pegylated 
liposomal formulation of doxorubicin given at the dose of 
30 mg/m2, based on regimens cited in the literature (11,12). 
The remaining medications were administered at standard 
doses. After the first cycle of chemotherapy there was some 
noticeable improvement in the extent of the RUE lesion. 
However, when blood counts decreased, the patient’s overall 
status started to deteriorate and his activity and oral intake 
significantly declined. The patient and the family desired 
for comfort and supportive care only. Therefore the patient 
Figure 1 Immunohistochemical studies of the specimen from core biopsies of the right upper extremity mass. The specimens were positive 
for CD20, Pax5, BCL2, and Ki67. The magnifications are 20× for the figures.
A
CD20
BCL 2
Pax5
Ki67
C
B
D
Stem Cell Investigation, 2016
© Stem Cell Investigation. All rights reserved. Stem Cell Investig 2016;3:25sci.amegroups.com
Page 3 of 5
was discharged to a hospice facility. 
Discussion
The analysis of the Surveillance, Epidemiology End 
Results Database between 2004 and 2009 identified 31.6% 
of DLBCL cases presenting with primary extranodal 
involvement. Gastrointestinal tract was the most common 
site (10.7%), followed by head and neck (4.3%), with skin 
and soft tissue representing 3.3% of cases. In the same 
population study extranodal presentation is related with 
older age, early presentation and, depending on location, 
incurs different prognosis. Better outcomes were observed 
with head and neck involvement, whereas worse outcomes 
with GI tract, liver, pancreas and lung involvement. In a 
single institution report combined with meta-analysis of 
published cases and case series (2), authors included a total 
of 83 patients with primary extranodal lymphoma. The 
most common subtype was DLBCL. Authors observed 
a trend towards inferior outcomes in DLBCL compared 
to indolent lymphomas and increased chance of CNS 
relapse. Because of the limitations of the data (lacking 
information about prognostic factors) and small sample 
size, no conclusion about best treatment options could 
have been made. In another single institution study of 262 
patients, authors compared outcomes of the nodal and 
extranodal DLBCL before and after introduction of the 
immunotherapy with rituximab to standard treatment (3). 
Authors point to the fact that the group with the greater 
benefit from the addition of rituximab was the primary 
nodal involvement DLBCL, emphasizing potential 
clinicobiological differences between the two groups, like 
IPI (international Prognostic Index) scores at presentation 
or single gene alterations (3,14). Cases involving soft 
tissues often mimic other entities like sarcomas, malignant 
melanoma, or metastatic carcinomas (14-22). In our case, 
the initial presentation, imaging studies, as well as fast 
growth of the lesion raised strong suspicion of a soft tissue 
sarcoma. Our patient presented with high risk disease. 
The first line therapy for this type of high risk DLBCL 
recommended by the National Comprehensive Cancer 
Network is R-CHOP or dose-adjusted R-EPOCH 
(4-8,23,24). However, about 50% of patients are above 60 
years old at the time of diagnosis. Therefore, regimens 
including alternatives to the cardiotoxic therapies have been 
investigated. Phase I and II studies incorporating liposomal 
form of doxorubicin showed promising results (11-13,23,24). 
The pegylated form of doxorubicin compared to traditional 
doxorubicin has longer half-life, reduced volume of 
distribution, as well preferential distribution into neoplastic 
tissues, at the same time carrying the benefit of lower 
toxicity and improved therapeutic activity (12,13). Other 
measures which might be implemented in order to reduce 
cardiac toxicity are to treat the patient with conventional 
doxorubicin in continuous infusion over 72–96 h (25) and 
to use dexrazoxane (26). The use of the latter however, 
raised concerns of increased myelotoxicity and possible 
tumor protective effect. Its administration in the setting 
of chemotherapy induced cardiomyopathy is currently 
limited to women with breast cancer, who had received a 
cumulative dose of doxorubicine of 300 mg/m2. Regimen 
with decreased doses of cyclophosphomide, doxorubicin, 
vincristine and prednisone (R-miniCHOP) is another 
possibility for frail patients older than 80 years old (27). In 
the patient presented in our report, the regimen containing 
liposomal doxorubicin was a reasonable choice in attempt to 
control an advanced, high-risk disease in an elderly patient 
with deteriorating performance status and decreased cardiac 
function. However, all of the above therapies carry a burden 
of significant toxicities and there is an increasing need for 
novel targeted agents for the treatment of the population of 
elderly and frail patients (28-34).
Conclusions
This patient represents an extremely rare case of RUE 
lymphoma, mimicking soft tissue sarcoma. This elderly 
patient with poor performance status and decreased cardiac 
function had limited treatment options. Novel targeted 
agents should be explored for this population of patients
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